ASCO abstracts are out, with data for ADCs, Nimbus’ next-gen I/O drug and more
Abstracts for the American Society of Clinical Oncology are out, with new data from Pfizer’s ADC, Nimbus Therapeutics’ immuno-oncology drug, Nuvation Bio’s ROS1 inhibitor and new data from J&J in prostate cancer. After $4B Takeda deal, Nimbus lays out ‘grand’ hopes for its next-gen immunotherapy drug: The company released updated